Argenx's 1.06% Gains Amid 28.68% Volume Drop Leave Stock 389th in Market Activity

On October 3, 2025, argenx (ARGX) closed with a 1.06% gain, while its trading volume of $0.28 billion marked a 28.68% decline from the previous day, ranking the stock 389th in market activity. The biotech firm’s performance reflects mixed investor sentiment amid evolving market dynamics.

Recent developments suggest renewed focus on argenx’s therapeutic pipeline, particularly its monoclonal antibody programs targeting autoimmune diseases. Analysts noted that regulatory updates or partnership progress could drive volatility, though current trading volumes indicate limited short-term catalysts. The stock’s modest rise contrasts with broader sector trends, highlighting niche investor interest.

To run this back-test accurately, I need to pin down a couple of practical details that aren’t fully specified yet: 1. Stock universe – Do you want to consider all U.S. listed common stocks (≈ 3 000+) or restrict the universe (e.g., S&P 500 constituents)? – If the broader universe is desired, please confirm that using only NYSE + NASDAQ issues (no OTC) works for you. 2. Trade price convention – Open-to-close: buy each day at the opening price and liquidate at that day’s close. – Close-to-close: buy at today’s close, sell at tomorrow’s close. The second option is more common for “hold-for-one-day” turnover strategies because it avoids the open auction gap. Which do you prefer? 3. Rebalancing mechanics – Equal-weight each of the 500 selected names (default). – Transaction costs: assume zero unless you want us to include an estimate. Once we lock these in, I’ll generate the daily selection list, create the trade signals, and run the portfolio back-test from 2022-01-03 (first trading day of 2022) to today.